Alnylam Pharma ( (ALNY) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alnylam Pharmaceuticals shares are jumping after the company reported strong topline data from its HELIOS-B Phase 3 trial of vutrisiran (Amvuttra) in patients with ATTR amyloidosis with cardiomyopathy. The trial hit its main goal, showing a clear reduction in the combined risk of death and repeat cardiovascular events, and also succeeded on all key secondary measures.
Analysts say this company-specific breakthrough is fueling hopes for regulatory approval and a major expansion of the drug’s market. The news has pushed Alnylam to its biggest single-day advance in nearly two years as investors reprice the stock’s long-term growth potential.
More about Alnylam Pharma
YTD Price Performance: -22.53%
Average Trading Volume: 1,360,925
Technical Sentiment Signal: Hold
Current Market Cap: $40.85B
For further insights into ALNY stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.